摘要
Even with the most potent,modern therapies,multiple myeloma(MM)remains a largely incurable disease.The reprogramming of a patient’s T-lymphocytes with a cancerassociated antigen-specific chimeric antigen receptor(CAR)has improved the outcome of patients with this debilitating disease.B cell maturation antigen(BCMA),a marker almost exclusively expressing by plasma cells,^(1) is the most attractive target for designing CAR-T cells against MM.
